Inhibition kinetics and gastrointestinal stability are evaluated in bioactive peptides, indicating potential for antihypertensive use.
The <1 kDa-PP V. unguiculata peptide fractions combine non-competitive ACE-I inhibition, high digestive stability, and low cytotoxicity, presenting potential as antihypertensive ingredients in functional foods and nutraceuticals. These findings warrant further investigation, including the identification of sequences within the active fractions and in vivo validation of antihypertensive efficacy.
No takes yet. Share an insight, caveat, or question.
Cú‐Cañetas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: